# A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

> **NCT01477853** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 166 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Atorvastatin
- **OTHER:** Placebo to sitagliptin
- **OTHER:** Placebo to atorvastatin
- **DRUG:** Metformin (open-label)
- **DRUG:** Glimepiride (open-label)
- **DRUG:** Glimepiride (double-blind)
- **DRUG:** Placebo to glimepiride

## Key facts

- **NCT ID:** NCT01477853
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10-24
- **Primary completion:** 2012-12-04
- **Final completion:** 2012-12-04
- **Target enrollment:** 166 (ACTUAL)
- **Why stopped:** The study was terminated early by the Sponsor for business reasons.
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01477853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01477853, "A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01477853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*